PGEN · Precigen, Inc.
$7.42
+0.14 (+1.92%)
At close · Aug 26
View the 10-Q filed May 13, 2026
Customer concentration
— top 4 customers 49.9% of revenue
4 customers — 49.9% of revenue (the three months ended March 31, 2025)
“For the three months ended March 31, 2025, four customers accounted for 49.9% of total condensed consolidated revenues.”
Market Cap
$2.66B
Shares
358.04M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.42
Open$7.66
Day$7.28–7.72
52W close$3.10–7.44
Avg vol 30d5.5M
Short int42.2M · 11.8% float · 5.9d
Short vol30%
Last earningsAug 4, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 4
Up next
Next earnings call
Nov 20, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 4, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+63%
above
Price vs 50-day avg
+25%
above
RSI (14)
66
neutral
MACD trend
Positive
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+36%
trailing
6-month return
+120%
trailing
YTD return
+78%
this year
Relative strength
+108%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $5 — 50d above 200d
Institutional flow
Accumulating
+1% holders QoQ · +35 funds added
Insider flow
Accumulating
Net +$24.7K over 90 days · 0% sells
Short interest
Rising
11.80% of float · ▲ +0.5% MoM · 5.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
209 holders — near 3-yr high, broad support
Squeeze score
73
high risk · 0–100
Fundamentals
Revenue growth
+21%
Y/Y
EPS growth
−191%
Y/Y
Free cash flow
$-89.8M
Balance sheet
$106.2M
net debt
Quant / Vol
risk profile
Volatility
82%
annualized · 1-yr
Max drawdown
−41%
past year
ATR
5.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Dec 31, 2025
Revenue
· 2026
$18M
Prior guidance
period ended
· from the Earnings Call filed Dec 31, 2025
Revenues
· Q1 2026
$18M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+63%
Bullish
Price vs 50-day avg
+25%
Bullish
RSI (14)
66
Neutral
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $6 › 200d $5 — 50d above 200d
Institutional flow
Accumulating
+1% holders QoQ · +35 funds added
Insider flow
Accumulating
Net +$24.7K over 90 days · 0% sells
Short interest
Rising
11.80% of float · ▲ +0.5% MoM · 5.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
209 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $7 · 100%
Range high $7
vs 200-day avg +63%
vs 50-day avg +25%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Payer coverage (US lives) | 315M | Q2 2026 | — |
| Private health plan coverage (US lives) | 215M | as of May 13, 2026 | — |
| Total payer coverage (US lives) | 297M | as of May 13, 2026 | — |
| Cash, cash equivalents, and investments | $100.4M | as of December 31, 2025 | — |
| PAPZIMEOS net product revenue | $3.4M | Q4 2025 | — |
| PAPZIMEOS patient hub enrollment | 300 | Full Year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PGEN
this stock
Precigen, Inc.
|
$2.66B | +77.5% | +21.0% | — | 11.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.79B | +20.7% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.89B | +5.6% | +20.8% | 20.2 | 2.3% |
|
ARGX
Argenx SE
|
$63.81B | +24.5% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.07B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PGEN | +3.6% | +36.2% | +120.2% | +18.3% | +77.5% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | +4.0% | +31.1% | +107.7% | +15.8% | +65.2% |
Key facts
CIK
1356090
CUSIP
74017N105
13F (30d)
178 filings
176 filers
Visit website
Investor relations